Biotechnology News and Research

RSS

TivaMed changes its name to Viveve

Women's sexual health company, TivaMed, today announced it has changed its name to Viveve as it prepares for a 2010 launch of its Viveve system to OB/GYNs in select U.S. markets.

9 Nov 2009

Clinipace acquires Worldwide Clinical Research, changes its name to Clinipace Worldwide

Clinipace, a global technology-driven clinical research organization (CRO), announced today that on October 26th, 2009 the company closed its acquisition of Worldwide Clinical Research, Inc. (WWCR), a Midwest-based CRO specializing in the management of clinical studies for biotechnology and pharmaceutical companies. With the acquisition, Clinipace has changed its name to Clinipace Worldwide.

9 Nov 2009

Cardiome Pharma announces financial results for the three months ended September 30, 2009

Cardiome Pharma Corp. today reported financial results for the third quarter ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

9 Nov 2009

BioMed Realty receives commitment from lenders to increase the borrowing capacity on its unsecured line of credit by $65 million

BioMed Realty Trust, Inc. (NYSE: BMR) announced today that the company has received commitments from lenders to increase the borrowing capacity on its unsecured line of credit by $65 million to an aggregate of $665 million, with no other changes to the terms of the facility.

9 Nov 2009

Compugen discovers new biomarker for predisposition to type 2 diabetes using its GeneVa platform

Compugen Ltd. announced today the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes, the most common form of diabetes.

9 Nov 2009

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

Clinical Data, Inc. today announced the Company’s operational and financial results for its second fiscal quarter ended September 30, 2009.

9 Nov 2009

Concert Pharmaceuticals commences Phase 1b clinical study of its CTP-518 HIV protease inhibitor

Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral HIV protease inhibitor for the treatment of HIV infection. In connection with the start of this multiple ascending dose arm of the Phase 1 study, Concert will receive a $12 million milestone payment under the company’s strategic alliance with GlaxoSmithKline.

9 Nov 2009

AMRI reports $47.7 million total revenue for the third quarter of 2009

AMRI today reported financial and operating results for the third quarter ended September 30, 2009.

9 Nov 2009

Nasdaq grants Anesiva's request for continued listing on The NASDAQ Global Market

Anesiva, Inc. today announced that on November 5, 2009, it received a letter from The NASDAQ Stock Market LLC stating that the Nasdaq Hearing Panel has granted Anesiva's request for continued listing on The NASDAQ Global Market subject to the condition that Anesiva shall have completed on or before December 31, 2009, the proposed merger (the "Merger") contemplated by the Agreement and Plan of Merger, dated August 4, 2009, among Anesiva, Arca Acquisition Corporation ("Arca"), a wholly-owned subsidiary of Anesiva, Arcion Therapeutics, Inc. ("Arcion") and, with respect to Articles V and IX only of the agreement, each of the Arcion stockholders listed on Schedule I thereto.

9 Nov 2009

PAREXEL International forms an alliance with Mortara Instrument, enhances cardiac safety capabilities

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has enhanced its cardiac safety capabilities for early phase clinical development through an alliance with Mortara Instrument, Inc., which manufactures and distributes electrocardiogram (ECG) devices and related technology worldwide.

From Parexel 9 Nov 2009

Bend Research signs collaboration agreement with Vertex Pharmaceuticals

Bend Research Inc., a company with more than 30 years of experience in applying innovative pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, announced today that it has entered into a collaboration with Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Cambridge, MA.

9 Nov 2009

PhRMA releases statement regarding the House health care reform bill

We are disappointed, but not surprised by today's vote -- an uneasiness echoed by millions of hardworking Americans as well as nearly half of the members of the U.S. House of Representatives who voted against the bill.

9 Nov 2009

Demand for products and services by life science industry is expected to grow rapidly

We Work for Health, an alliance of Washington state business, academic, government and community leaders, today released the results of a first-of-its-kind economic impact study showing that employment in Washington's life sciences sector has passed many of the traditional resource-based industries on which the state's economy was founded, and is in the same range of importance as some of the new, technology-based industries of the state.

7 Nov 2009

Locus Pharmaceuticals creates a new division, Ansaris

Locus Pharmaceuticals, a drug company that has developed its own internal and partnered pipeline, focusing on oncology, immunology, and inflammatory targets, today announced that in conjunction with a transformation to a drug discovery collaboration business model, it has created a new division, Ansaris, which will include most of its operations and personnel.

7 Nov 2009

PPD acquires Excel PharmaStudies

PPD, Inc. today announced it has completed its acquisition of Excel PharmaStudies, Inc., the market leader and one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.

7 Nov 2009

GeoVax Labs announces financial results and operational update for the third quarter of 2009

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update.

6 Nov 2009

'Hormone of darkness' melatonin regulates sleep effectively

Melatonin, a natural hormone segregated by the own human body, is an excellent sleep regulator expected to replace somniferous, which are much more aggressive, to correct the sleep/wakefulness pace when human biological clock becomes altered.

6 Nov 2009

Broad Institute purchases 30 additional Genome Analyzers from Illumina

Illumina, Inc. today announced that the Broad Institute has purchased 30 additional Genome Analyzers, increasing its total installed base of Illumina systems to 89.

From Illumina, Inc. 6 Nov 2009

TREANDA induces durable responses in indolent B-cell non-Hodgkin's lymphoma patients

Cephalon, Inc. today announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with rituximab.

6 Nov 2009

Revised Management Guidelines for diagnosing and treating thyroid cancer released

The American Thyroid Association has released new, revised Management Guidelines for the diagnosis and treatment of patients with thyroid nodules and thyroid cancer. The new guidelines are published in Thyroid, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com).

6 Nov 2009

Biotechnology News and Research

TivaMed changes its name to Viveve

Clinipace acquires Worldwide Clinical Research, changes its name to Clinipace Worldwide

Cardiome Pharma announces financial results for the three months ended September 30, 2009

BioMed Realty receives commitment from lenders to increase the borrowing capacity on its unsecured line of credit by $65 million

Compugen discovers new biomarker for predisposition to type 2 diabetes using its GeneVa platform

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

Concert Pharmaceuticals commences Phase 1b clinical study of its CTP-518 HIV protease inhibitor

AMRI reports $47.7 million total revenue for the third quarter of 2009

Nasdaq grants Anesiva's request for continued listing on The NASDAQ Global Market

PAREXEL International forms an alliance with Mortara Instrument, enhances cardiac safety capabilities

Bend Research signs collaboration agreement with Vertex Pharmaceuticals

PhRMA releases statement regarding the House health care reform bill

Demand for products and services by life science industry is expected to grow rapidly

Locus Pharmaceuticals creates a new division, Ansaris

PPD acquires Excel PharmaStudies

GeoVax Labs announces financial results and operational update for the third quarter of 2009

'Hormone of darkness' melatonin regulates sleep effectively

Broad Institute purchases 30 additional Genome Analyzers from Illumina

TREANDA induces durable responses in indolent B-cell non-Hodgkin's lymphoma patients

Revised Management Guidelines for diagnosing and treating thyroid cancer released

Biotechnology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News